Global Gene Delivery Technologies Market (2021 to 2028) – Share, Size, Trends, Industry Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Gene Delivery Technologies Market Share, Size, Trends, Industry Analysis Report, By Mode; By Application; By Method; By Regions; Segment Forecast, 2021 -2028” report has been added to ResearchAndMarkets.com’s offering.

The global gene delivery technologies market size is expected to reach USD 7.86 billion by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

In 2020, the gene therapy market segment accounted for the largest share. Worldwide acceptance of gene therapies and subsequent rise in clinical research activities have boosted the segment’s market growth. Moreover, rising approvals for gene therapy products and services also accelerated the gene delivery technologies market growth prospects.

The vaccine market segment is projected to witness a lucrative growth rate over the gene delivery technologies study period. This is primarily due to the ability of such vaccines for different treatment approaches for both preventive and therapeutic areas. They have the potential to activate potent humoral responses. This has boosted the demand for gene editing tools for vaccine development.

The gene delivery technologies market segment is anticipated to benefit from a sudden rise in COVID-19 cases. As of August 2020, more than 25 research groups have been working for vector-based vaccines to contain COVID-19 infection. Similarly, approximately 20 research teams are exploring approaches to develop nucleic acid vaccines.

Market participants in gene delivery technologies industry include Horizon Discovery Group Co., QIAGEN, Oxford Biomedica, SignaGen Laboratories, Hoffmann-La Roche AG, Vectalys, Sirion-Biotech GmbH, Takara Bio Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., OriGene Technologies, Inc., System Biosciences, Promega Corporation, and Catalent Inc.

The market players operating in the gene delivery technologies industry are focusing on mergers and acquisitions to stay competitive in the market. In line with this, in May 2020, Merck, completed the acquisition of Themis, an immune-modulation therapy to expand its vaccine development program for the surging COVID-19 numbers. Similarly, earlier, in May 2019, already acquired Brammer Bio, a US-based company engaged in the development of viral vectors to be used in gene therapies.

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Gene Delivery Technologies Market Insights

4.1. Gene Delivery Technologies – Industry snapshot

4.2. Gene Delivery Technologies Market Dynamics

4.3. Porter’s Five Forces Analysis

4.4. PESTLE Analysis

4.5. Gene Delivery Technologies Market Industry trends

5. Gene Delivery Technologies Market Assessment by Mode

5.1. Key Findings

5.2. Introduction

5.3. Biological

5.4. Chemical

5.5. Physical

6. Global Gene Delivery Technologies Market, by Application

6.1. Key Findings

6.2. Introduction

6.3. Gene Therapy

6.4. Cell Therapy

6.5. Vaccines

6.6. Research

7. Gene Delivery Technologies Market Assessment by Method

7.1. Key Findings

7.2. Introduction

7.3. Ex vivo

7.4. In vivo

7.5. In vitro

8. Gene Delivery Technologies Market Assessment by Geography

8.1. Key findings

8.2. Introduction

8.3. Gene Delivery Technologies Market – North America

8.4. Gene Delivery Technologies Market – Europe

8.5. Gene Delivery Technologies Market – Asia-Pacific

8.6. Gene Delivery Technologies Market – Middle East & Africa

8.7. Gene Delivery Technologies Market – Latin America

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis

9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Thermo Fisher Scientific, Inc.

10.2. Horizon Discovery Group Co.

10.3. OriGene Technologies, Inc.

10.4. Oxford Biomedica

10.5. SignaGen Laboratories

10.6. Takara Bio Inc.

10.7. System Biosciences llc

10.8. Promega Corporation

10.9. F. Hoffmann – La Roche AG

10.10. QIAGEN

10.11. Vectalys

10.12. Bio – Rad Laboratories, Inc.

10.13. Catalent Inc.

10.14. Agilent Technologies

10.15. Sirion – Biotech GmbH

For more information about this report visit https://www.researchandmarkets.com/r/ivt02u

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900